Cargando…

Depatux-M and temozolomide in advanced high-grade glioma

Detalles Bibliográficos
Autores principales:	Hirsch, Sophie, Roggia, Cristiana, Biskup, Saskia, Bender, Benjamin, Gepfner-Tuma, Irina, Eckert, Franziska, Zips, Daniel, Malek, Nisar P, Wilhelm, Helmut, Renovanz, Mirjam, Tabatabai, Ghazaleh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367419/ https://www.ncbi.nlm.nih.gov/pubmed/32705082 http://dx.doi.org/10.1093/noajnl/vdaa063

Ejemplares similares

Integrative assessment of brain and bone invasion in meningioma patients
por: Zwirner, Kerstin, et al.
Publicado: (2019)

CNS Invasion in Meningioma—How the Intraoperative Assessment Can Improve the Prognostic Evaluation of Tumor Recurrence
por: Behling, Felix, et al.
Publicado: (2020)

H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort
por: Behling, Felix, et al.
Publicado: (2020)

EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand
por: Hoogstrate, Youri, et al.
Publicado: (2019)

Tumortherapieassoziierte neurologische Symptome
por: Renovanz, Mirjam, et al.
Publicado: (2021)

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
por: Van Den Bent, Martin, et al.
Publicado: (2020)

Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
por: van den Bent, Martin, et al.
Publicado: (2020)

Correction to: Retrospective analysis of fractionated intensity-modulated radiotherapy (IMRT) in the interdisciplinary management of primary optic nerve sheath meningiomas
por: Eckert, Franziska, et al.
Publicado: (2020)

Retrospective analysis of fractionated intensity-modulated radiotherapy (IMRT) in the interdisciplinary management of primary optic nerve sheath meningiomas
por: Eckert, Franziska, et al.
Publicado: (2019)

High Expression of Somatostatin Receptors 2A, 3, and 5 in Corticotroph Pituitary Adenoma
por: Behling, Felix, et al.
Publicado: (2018)

ATRX immunostaining predicts IDH and H3F3A status in gliomas
por: Ebrahimi, Azadeh, et al.
Publicado: (2016)

Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO)
por: Padovan, Marta, et al.
Publicado: (2021)

Cerebrospinal fluid cytokine levels are associated with macrophage infiltration into tumor tissues of glioma patients
por: Kemmerer, Constanze L., et al.
Publicado: (2021)

COX2 expression is associated with proliferation and tumor extension in vestibular schwannoma but is not influenced by acetylsalicylic acid intake
por: Behling, Felix, et al.
Publicado: (2019)

Retrospective analysis of recurrence patterns and clinical outcome of grade II meningiomas following postoperative radiotherapy
por: Hoffmann, Elgin, et al.
Publicado: (2021)

Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options
por: Bitzer, Michael, et al.
Publicado: (2020)

Impact of (18)F-FET PET/MRI on Clinical Management of Brain Tumor Patients
por: Brendle, Cornelia, et al.
Publicado: (2022)

Temozolomide in malignant glioma
por: Dresemann, Gregor
Publicado: (2010)

ACT-26 ABT-414 (DEPATUX-M) IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: WHERE DO WE STAND?
por: Preusser, Matthias
Publicado: (2019)

The role of Simpson grading in meningiomas after integration of the updated WHO classification and adjuvant radiotherapy
por: Behling, Felix, et al.
Publicado: (2020)

Differences in the expression of SSTR1–5 in meningiomas and its therapeutic potential
por: Behling, Felix, et al.
Publicado: (2021)

Frequent FGFR1 hotspot alterations in driver-unknown low-grade glioma and mixed neuronal-glial tumors
por: Engelhardt, Sophie, et al.
Publicado: (2022)

Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system
por: Renovanz, Mirjam, et al.
Publicado: (2023)

Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts
por: Porath, Kendra A, et al.
Publicado: (2022)

A Continuous Correlation Between Residual Tumor Volume and Survival Recommends Maximal Safe Resection in Glioblastoma Patients: A Nomogram for Clinical Decision Making and Reference for Non-Randomized Trials
por: Skardelly, Marco, et al.
Publicado: (2021)

Editorial: Quality of care of glioma patients
por: Forster, Marie-Therese, et al.
Publicado: (2022)

Corrigendum: Editorial: Quality of care of glioma patients
por: Forster, Marie-Therese, et al.
Publicado: (2022)

Association of dynamic susceptibility magnetic resonance imaging at initial tumor diagnosis with the prognosis of different molecular glioma subtypes
por: Brendle, Cornelia, et al.
Publicado: (2020)

Correction to: Association of dynamic susceptibility magnetic resonance imaging at initial tumor diagnosis with the prognosis of different molecular glioma subtypes
por: Brendle, Cornelia, et al.
Publicado: (2021)

Glioma patients in outpatient care—optimization of psychosocial care in neuro-oncological patients (GLIOPT): Protocol for a cluster randomized controlled trial
por: Renovanz, Mirjam, et al.
Publicado: (2020)

Inhibition of DNA Repair in Combination with Temozolomide or Dianhydrogalactiol Overcomes Temozolomide-Resistant Glioma Cells
por: Ohba, Shigeo, et al.
Publicado: (2021)

Temozolomide Chemotherapy in Patients with Recurrent Malignant Gliomas
por: Yang, Seung-Ho, et al.
Publicado: (2006)

The strategy for enhancing temozolomide against malignant glioma
por: Nakada, Mitsutoshi, et al.
Publicado: (2012)

Targeting autophagy to sensitive glioma to temozolomide treatment
por: Yan, Yuanliang, et al.
Publicado: (2016)

Glioma and temozolomide induced alterations in gut microbiome
por: Patrizz, Anthony, et al.
Publicado: (2020)

Temozolomide Chronotherapy in Glioma: A Systematic Review
por: Jia, Jason L., et al.
Publicado: (2023)

Piperine synergistically enhances the effect of temozolomide against temozolomide-resistant human glioma cell lines
por: Jeong, Somi, et al.
Publicado: (2020)

Dynamic Susceptibility Perfusion Imaging for Differentiating Progressive Disease from Pseudoprogression in Diffuse Glioma Molecular Subtypes
por: Richter, Vivien, et al.
Publicado: (2021)

Tissue metabolites in diffuse glioma and their modulations by IDH1 mutation, histology, and treatment
por: Trautwein, Christoph, et al.
Publicado: (2022)

Extended-schedule dose-dense temozolomide in refractory gliomas
por: Berrocal, A., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_3fbvg4tjs1u2s3sv7lf070du24